What are the VA rating percentages for Monoclonal Gammopathy of Undetermined Significance (MGUS)?

Monoclonal Gammopathy of Undetermined Significance (MGUS) (DC 7712) is rated at 0% under 38 CFR § 4.117, DC 7712 (Multiple myeloma; MGUS = 0% tier). Asymptomatic, smoldering, or monoclonal gammopathy of undetermined significance (MGUS)

What rates 0% for Monoclonal Gammopathy of Undetermined Significance (MGUS) under 38 CFR § 4.117, DC 7712 (Multiple myeloma; MGUS = 0% tier)?

Under 38 CFR § 4.117, DC 7712 (Multiple myeloma; MGUS = 0% tier) (DC 7712), a 0% rating for Monoclonal Gammopathy of Undetermined Significance (MGUS) requires: Asymptomatic, smoldering, or monoclonal gammopathy of undetermined significance (MGUS)

What happens during a C&P exam for Monoclonal Gammopathy of Undetermined Significance (MGUS)?

Blood-disorder ratings turn on objective measures - platelet counts, transfusion frequency, and the intensity of treatment (38 CFR 4.117). Bring your recent CBC and lab results. For immune thrombocytopenia (DC 7705), the rating is driven by your platelet count and whether you require chemotherapy or immunosuppressive therapy - document both.

← All Condition Guides

CLAIM RECON INTEL

Monoclonal Gammopathy of Undetermined Significance (MGUS)

Q: What evidence do I need for a Monoclonal Gammopathy of Undetermined Significance (MGUS) VA claim?

Key evidence for a Monoclonal Gammopathy of Undetermined Significance (MGUS) claim includes: Recent CBC and lab reports showing platelet count, hemoglobin, and neutrophil/ANC values; Transfusion records showing the number of platelet or red-cell transfusions per 12 months; A dated log of painful (vaso-occlusive) crises (sickle cell anemia); Hematology/oncology records documenting active disease or treatment-phase dates; Documentation of treatment intensity (continuous medication, immunosuppressive therapy, growth factors, or chemotherapy). All evidence should document both the condition and its impact on daily functioning.

DC 771238 C.F.R. § 4.117

Diagnostic Code

DC 7712

38 C.F.R. § 4.117

Rating Range

0–0%

1 severity tier

Source

Verified

38 C.F.R. § 4.117

Monoclonal Gammopathy of Undetermined Significance (MGUS) is rated by the U.S. Department of Veterans Affairs under DC 7712 of 38 CFR § 4.117, DC 7712 (Multiple myeloma; MGUS = 0% tier) across 1 severity tier (0%). Service connection requires (1) a current diagnosis, (2) an in-service event, injury, or exposure, and (3) a medical nexus opinion linking the two under 38 C.F.R. § 3.303.

Educational tool only. Not legal or medical advice. Not affiliated with the VA.

Overview

Blood condition where an abnormal protein (monoclonal protein or M protein) is found in the blood. Can progress to multiple myeloma or other blood cancers. Presumptive for Agent Orange exposure under the PACT Act. Requires lifelong monitoring.

Rating Criteria

Asymptomatic, smoldering, or monoclonal gammopathy of undetermined significance (MGUS)

Key Evidence

—Recent CBC and lab reports showing platelet count, hemoglobin, and neutrophil/ANC values

—Transfusion records showing the number of platelet or red-cell transfusions per 12 months

—A dated log of painful (vaso-occlusive) crises (sickle cell anemia)

—Hematology/oncology records documenting active disease or treatment-phase dates

—Documentation of treatment intensity (continuous medication, immunosuppressive therapy, growth factors, or chemotherapy)

—Bone marrow biopsy or other diagnostic reports confirming the condition

C&P Exam Tips

1Blood-disorder ratings turn on objective measures - platelet counts, transfusion frequency, and the intensity of treatment (38 CFR 4.117). Bring your recent CBC and lab results.

2For immune thrombocytopenia (DC 7705), the rating is driven by your platelet count and whether you require chemotherapy or immunosuppressive therapy - document both.

3For anemias requiring transfusion (for example, aplastic anemia, myelodysplastic syndromes), count how many transfusions of platelets or red cells you need per 12 months - that frequency sets the level.

4For sickle cell anemia (DC 7714), the rating counts painful (vaso-occlusive) crises per 12 months and the level of work you can still do - keep a dated log of every crisis.

5Active disease or an active treatment phase (chemotherapy) often supports a 100% evaluation for blood cancers - make sure your treatment dates are on the record.

6Report how fatigue, infections, or bleeding affect work and daily activity, and list all medications including any continuous or immunosuppressive therapy.

Tools

Rating Calculator →Secondaries Explorer →C&P Exam Prep →PACT Act Scanner →2026 Rates →

Sources & Editorial

Rating criteria text quoted verbatim from 38 C.F.R. § 4.117 (Hemic and lymphatic systems). Source verified 2026-06-05 by ClaimRecon Editorial Team against the Cornell Law CFR mirror; eCFR.gov is the authoritative government source.

View § 4.117 on eCFR →Cornell Law mirror →Editorial Standards →Suggest a correction →

EDUCATIONAL TOOL ONLY. NOT LEGAL OR MEDICAL ADVICE.
NOT AFFILIATED WITH THE U.S. DEPARTMENT OF VETERANS AFFAIRS.
CLAIM RECON 2026

LOADING